Dystrophin deficiency impairs cell junction formation during embryonic myogenesis.
Elise MozinEmmanuelle MassouridesVirginie MournetasClémence LièvreAudrey BourdonDana L JacksonJonathan S PackerCole TrapnellCaroline Le GuinerOumeya AdjaliChristian PinsetDavid L MackJean-Baptiste DupontPublished in: bioRxiv : the preprint server for biology (2023)
Mutations in the DMD gene lead to Duchenne muscular dystrophy, a severe X-linked neuromuscular disorder which manifests itself as young boys acquire motor functions. DMD is diagnosed after 2 to 4 years, but the absence of dystrophin has an impact before symptoms appear in patients, which poses a serious challenge in the optimization of standards of care. In this report, we investigated the early consequences of dystrophin deficiency during skeletal muscle development. We used single-cell transcriptome profiling to characterize the myogenic trajectory of human pluripotent stem cells and showed that DMD cells bifurcate to an alternative branch when they reach the somite stage. Here, dystrophin deficiency was linked to marked dysregulations of cell junction families involved in the cell state transitions characteristic of somitogenesis. Altogether, this work demonstrates that in vitro , dystrophin deficiency has early consequences during myogenic development, which should be considered in future therapeutic strategies for DMD.
Keyphrases
- duchenne muscular dystrophy
- single cell
- skeletal muscle
- rna seq
- muscular dystrophy
- pluripotent stem cells
- cell therapy
- high throughput
- healthcare
- insulin resistance
- end stage renal disease
- endothelial cells
- replacement therapy
- genome wide
- ejection fraction
- cell death
- chronic kidney disease
- cell proliferation
- gene expression
- newly diagnosed
- signaling pathway
- chronic pain
- adipose tissue
- metabolic syndrome
- copy number
- dna methylation
- sleep quality
- physical activity
- current status
- transcription factor
- affordable care act
- induced pluripotent stem cells
- cell cycle arrest